Medical Cannabis Advocacy in Mexico During the 2000s

Context: prohibition and the early drug war

Mexico entered the 2000s under a strict prohibition regime. Cannabis had been illegal since 1920, and the country's drug policy was heavily shaped by cooperation with the United States ^[1]. The election of Vicente Fox in 2000 ended seven decades of PRI rule and briefly raised expectations of policy reform, but drug law liberalization was not a Fox administration priority.

By the mid-2000s, the framing of cannabis in Mexican public life was dominated by trafficking violence, not medicine. When Felipe Calderón took office in December 2006 and launched a militarized offensive against drug cartels, the political space for a medical cannabis conversation narrowed further ^[2]. Advocacy in this decade therefore developed in the shadow of the drug war rather than as a mainstream health debate.

Who was actually advocating

There was no large patient movement in Mexico in the 2000s comparable to those in California or Canada. Advocacy came from a few overlapping circles:

• Harm-reduction and drug-policy NGOs. Organizations such as Espolea and the Colectivo por una Política Integral hacia las Drogas (CUPIHD, founded 2010 but with 2000s roots) argued for treating drug use as a public health issue ^[3].
• Academic researchers. Scholars at CIDE and UNAM, including Jorge Hernández Tinajero and later Catalina Pérez Correa, published critiques of prohibition and documented incarceration patterns for low-level possession ^[4].
• International-facing reformers. Mexican participants engaged with the Transnational Institute and the Washington Office on Latin America (WOLA) on regional drug policy reform ^[5].

Medical-cannabis-specific advocacy — patients publicly using cannabis as medicine — was rare and mostly invisible in this decade. The high-profile patient cases that reshaped Mexican opinion, such as that of Grace Elizalde, did not emerge until 2015 ^[6].

The 2009 Ley de Narcomenudeo

The decade's defining legal event came at its very end. In August 2009, Congress passed reforms — commonly called the Ley de Narcomenudeo — that decriminalized possession of small amounts of several drugs, including up to 5 grams of cannabis, for personal use ^[7][8].

This law is often retrospectively described as a victory for cannabis reformers. That framing is misleading Disputed. The reform's stated purpose was to let federal authorities focus on large traffickers while pushing small users into treatment or state-level enforcement. It did not create any medical cannabis framework, did not allow cultivation, and did not authorize sales. Possession above the threshold remained criminal, and the treatment referrals created new points of contact with the justice system rather than fewer ^[4][8].

Still, the law was significant. It was the first time the Mexican federal government formally acknowledged that criminalizing users was distinct from — and less useful than — pursuing traffickers. That conceptual shift became a foothold for later medical arguments.

What the 2000s did not produce

Several claims about this period circulate in cannabis-industry marketing and reform retrospectives. Some are wrong or exaggerated:

• "Mexico had a medical cannabis movement in the 2000s comparable to the US." No data It did not. There was no state-level medical program, no dispensary system, and no meaningful patient-registry advocacy in this decade.
• "The 2009 law legalized cannabis." Disputed It decriminalized possession of up to 5 grams. Cultivation, sale, and larger possession remained criminal offenses ^[7].
• "Vicente Fox was a cannabis reform advocate." Weak / limited Fox became a vocal legalization advocate after leaving office, particularly from around 2010 onward ^[9]. During his 2000–2006 presidency, his administration did not pursue cannabis reform; a 2006 decriminalization bill under Fox was withdrawn under US pressure ^[1][2].
• "Grassroots patient activism drove the 2009 law." No data The law was a government-led response to drug-war pressures, drafted primarily by the Calderón administration and Congress, not by patient groups.

Legacy: how the 2000s set up the 2010s

The real contribution of 2000s advocacy was infrastructural. The decade produced:

1. A policy vocabulary. By 2009, Mexican legislators and journalists were comfortable distinguishing users from traffickers — a prerequisite for later medical framing.
2. A small expert bench. Researchers and NGO staff who had spent the 2000s critiquing prohibition became the go-to voices when the Supreme Court began hearing amparo cases in the 2010s ^[4][6].
3. International linkages. Mexican reformers were embedded in regional networks by the decade's end, positioning them to influence the 2016 UNGASS special session on drugs, which Mexico co-sponsored ^[5].

The visible wins — the SCJN's 2015 ruling in favor of the SMART amparo group, the 2017 medical cannabis law, and the 2021 Supreme Court declaration that recreational prohibition was unconstitutional — belong to the 2010s and 2020s. But they rested on legal and civil-society scaffolding built, quietly, in the 2000s ^[6][10].

Sources

How this page was made